TRIM29 (h): 293T Lysate: sc-112361



The Power to Question

BACKGROUND

Ataxia-telangiectasia (AT) is an autosomal recessive human genetic disease characterized by an elevated risk of cancer, immune defects, genetic instability and an increased sensitivity to radiation. For example, 10-15% of AT patients suffer an extremely high incidence of lymphoid malignancies incuding both T and B cell tumors by early adulthood. Interestingly, there is a total absence of myloid tumors in these patients. Although AT homozygotes are rare, the AT gene is likely to play a role in sporadic breast cancer and other common cancers. The human AT gene has been mapped to chromosome 11q23.3. The AT group D complementing gene has been cloned. The protein, designated TRIM29, or ATDC, has been shown to interact with the intermediate filament protein vimentin, a substrate for the PKC family of protein kinases, and with hPKCl-1, an inhibitor of the PKCs. Examination of the predicted TRIM29 amino acid sequence has revealed the presence of both zinc finger and leucine zipper motifs, suggesting that the protein may form homodimers and possibly associate with DNA.

REFERENCES

- 1. Kapp, L.N., Painter, R.B., Yu, L.C., van Loon, N., Richard, C.W., III., James, M.R., Cox, D.R. and Murnane, J.P. 1992. Cloning of a candidate gene for ataxia telangiectasia group D. Am. J. Hum. Genet. 51: 45-54.
- 2. Richard, C.W., III., Cox, D.R., Kapp, L., Murnane, J., Cornelis, F., Julier, C., Lathrop, G.M. and James, M.R. 1993. A radiation hybrid map of human chromosome 11q22-q23 containing the ataxia telangiectasia disease locus. Genomics 17: 1-5.
- 3. Murnane, J.P., Zhu, Y., Young, B.R. and Christman, M.F. 1994. Expression of the candidate AT gene ATDC is not detectable in a human cell line with a normal response to ionizing radiation. Intl. J. Radiat. Biol. 66: S77-S84.
- 4. Leonhardt, E.A., Kapp, L.N., Young, B.R. and Murnane, J.P. 1994. Nucleotide sequence analysis of a candidate gene for ataxia telangiectasia group D (ATDC). Genomics 19: 130-136.
- Meyn, M.S. 1995. Ataxia telangiectasia and cellular responses to DNA damage. Cancer Res. 55: 5991-6001.
- Brzoska, P.M., Chen, H., Zhu, Y., Levin, N.A., Disatnik, M.H., Mochly-Rosen, D., Murnane, J.P. and Christman, M.F. 1995. The product of the ataxiatelangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor. Proc. Natl. Acad. Sci. USA 92: 7824-7828.
- 7. Taylor, A.M., Metcalfe, J.A., Thick, J. and Mak, Y.F. 1996. Leukemia and lymphoma in ataxia telangiectasia. Blood 87: 423-438.

CHROMOSOMAL LOCATION

Genetic locus: TRIM29 (human) mapping to 11q23.3.

PRODUCT

TRIM29 (h): 293T Lysate represents a lysate of human TRIM29 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

TRIM29 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive TRIM29 antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.


TRIM29 (B-11): sc-374074 is recommended as a positive control antibody for Western Blot analysis of enhanced human TRIM29 expression in TRIM29 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA







TRIM29 (C-2): sc-376125. Western blot analysis of TRIM29 expression in non-transfected: sc-117752 (A) and human TRIM29 transfected: sc-112361 (B) 293T whole cell Ivsates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com